natgillin/translations-raw huggingface dataset:
The method of claim 5 or 6, further comprising the step of amplifying a nucleotide sequence and detecting in the sample the amplified nucleotide sequence. 
Postupak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što ga čini dodatni korak umnožavanja nukleotidnog slijeda i detektiranje u uzorku umnoženog nukleotidnog slijeda.
Adhesive system as claimed in claim 4, wherein the adhesive system, in addition to any urea present in the urea based amino resin, comprises no urea. 
Adhezivni sustav u skladu s patentnim zahtjevom 4, naznačen time što adhezivni sustav, uz bilo koju količinu uree prisutnu u amino-smoli na bazi uree, ne sadrži ureu.
a method of treating a subject for cancer refractory to a chemotherapy and/or radiotherapy, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition; 
liječenju raka u subjekta čiji je rak refraktoran na standarni režim liječenja, koje obuhvaća primjenu terapijski učinkovite količine spoja formule VIII subjektu;
A method for preparing a composition comprising the step of admixing a compound or a pharmaceutically acceptable derivative of the compound according to any one of claims 1-13 and a pharmaceutically acceptable carrier or excipient. Use of a compound according to any one of claims 1-13 for the manufacture of a medicament useful for treating pain, a memory disorder, obesity, constipation, urinary incontinence, anxiety, cough, diarrhea, high blood pressure, epilepsy, anorexia/cachexia, or drug abuse in an animal. 
Metoda za pripremu sastava koja sadrži korak umješavanja spoja ili farmaceutski prihvatljivog derivata spoja prema bilo kojem zahtjevu od 1 do 19 i farmaceutski prihvatljivog nosača ili ekscipijensa, naznačena time da je farmaceutski prihvatljiv derivat odabran iz skupine: farmaceutski prihvatljivih soli, solvata, radiomarkiranih derivata, stereoizomera, enantiomera, dijastereoizomera, drugih stereoizomerskih oblika, racemičnih smjesa, geometrijskih izomera i/ili tautomera.
A system according to claim 3, wherein said EMR tuner (210) is further adapted to maximise energy transfer from the electromagnetic radiation (EMR) to the energised fluid substance injected into the reactor chamber (103) of the fuel activation and energy release apparatus. 
Sustav prema Zahtjevu 3, gdje je navedeni uređaj (210) za podešavanje elektromagnetnog zračenja dalje prilagođen da maksimizira prijenos energije iz elektromagnetnog zračenja (EMR) na pobuđenu supstancu u obliku fluida koja je ubrizgana u komoru (103) reaktora uređaja za aktivaciju goriva i otpuštanje energije.
[Item 11] The medicament of Item 10, wherein said serotonin and norepinephrine reuptake inhibitor is at least one drug selected from the group consisting of venlafaxine, duloxetine, milnacipran, desvenlafaxine and salts thereof. 
Medikament prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se kod navedenog lijeka (II) radi o inhibitoru povratne apsorpcije serotonina i noradrenalina, koji je najmanje jedan lijek odabaran iz skupine koju čine venlafaksin, duloksetin, milnacipran, desvenlafaksin i njihove soli.
For example, the active agent may be added in the form of a micronised powder, an ethanolic solution, or an aqueous solution. 
Na primjer, aktivno sredstvo se može dodavati u obliku mikroniziranog praška, otopine u etanolu ili vodene otopine.
A process according to either claim 1 or claim 2, wherein the tobacco material has a packing density on a dry matter weight base of between 200 kg/m3 and 500 kg/m3, and/or wherein the tobacco material has a moisture content of between 10% and 18% before and during the treatment, and/or wherein the tobacco material is secured within the moisture-retaining material for between 5 and 65 days, and/or wherein the tobacco material is exposed to an ambient processing temperature of above 55°C. 
Postupak u skladu s bilo patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što duhanski materijal ima gustoću pakiranja na osnovi težine suhe tvari između 200 kg/m? i 500 kg/m", i/ili što duhanski materijal ima sadržaj vlage između 10 % i 18 % prije i tijekom obrade, i/ili što je duhanski materijal osiguran unutar materijala koji zadržava vlagu u trajanju između 5 i 65 dana, i/ili što je duhanski materijal izložen okolišnoj temperaturi obrade iznad 55 "€.
c)reacting the compound of the formula (V) with 4-chloro-3-trifluoromethyl-phenyl isocyanate to give the compound of the formula (II). 
reakcije spoja s formulom (V) s 4-kloro-3-trifluorometil-fenil izocijanatom da se dobije spoj s formulom (II).
The method according to Claim 2 or 3 wherein the first solvent is a primary alcohol, a secondary alcohol, or a tertiary alcohol. 
Postupak u skladu s patentnim zahtjevom 2 ili 3, naznačen time, da je prvo otapalo primarni alkohol, sekundarni alkohol ili tercijarni alkohol.
In a second aspect of the invention, there is provided a compound according to the invention in its first aspect, for use in therapy. 
U drugom aspektu izuma, donosi se spoj prema izumu u njegovom prvom aspektu, za upotrebu u terapiji.
A composition according to claim 1, wherein the amount of composition which is to be applied to the affected area ranges from about 0.1 g/cm2 to about 5 g/cm2 of skin surface area. 
Spoj prema zahtjevu 1, naznačen time da se količina koju treba nanijeti na zahvaćeno područje kreće od oko 0,1 g/em" do oko 5 g/em" površine kože.
The ED50 value for the tremor inhibitory activity of tolperisone alone was 55.0 ± 7.2 mg/kg, while when combined with dextromethorphan at a ratio of 5:1 it had an ED50 of 33.0 ± 0.7 mg/kg. 
Vrijednost EDs, za djelovanje samog tolperisona u smislu inhibicije tremora bila je 55,0+7,2 mg/kg, dok je u kombinaciji s dekstrometorfanom kod omjera 5:1 on imao ED, od 33,0+0,7 mg/kg.
A GPS receiver (11) for receiving a current position signal from a satellite (15); 
- GPS prijemnik (11) za prijem signala trenutnog položaja od satelita (15);
Protein purification usually requires some type of chromatography separation (see review by Constans 2002). 
Pročišćavanje proteina obično zahtjeva neki tip kromatografskog razdvajanja (vidi pregledni članak Constans
Likewise, discontinuation of the oral contraceptive pill has little scientific support. 
Slično, prekid uzimanja oralnih kontracepcijskih pilula nije znanstveno značajno dokazano kao učinkovito.
The organic phase was dried over Na2CO3, filtered and evaporated to yield a brown oil, which was triturated with water. 
Organska faza se osuši preko MgSO,, filtrira i uparava do dobivanja smeđeg ulja, koje se triturira sa vodom.
In certain embodiments, the EGFRvIII polypeptide sequences of the present invention are expressed as a fusion protein comprising an in frame secretory signal sequence, thereby resulting in their secretion as soluble polypeptide(s) by the bacterium. 
Izolirana molekula nuklemske kiseline prema zahtjevu 5 ili 6, naznačena time, da molekula nuklemske kiseline kodira navedeni ununogeni polipeptid kao fuzijski protein koji sadrži sekrecijski signalni slijed.
Besides, the particle size of the said pellets is highly suitable for pharmaceutical purposes, and the yield of the product fraction exceeds 75%. Details of the invention 
K tome, veličina čestica navedenih granula prilagođena je farmaceutskim potrebama, pa tako prinos frakcije produkta premašuje 75%.
Method according to claim 6, wherein said nucleic acid probe or primer has a detectable label. 
Postupak sukladno patentnom zahtjevu 6, pri čemu sukladno funkcijska sonda nukleinske kiseline ili početnica nukleinske kiseline ima detektibilnu oznaku.
It should be remarked that in the reduction step during casting the feed speed of the material is constant. 
Potrebno je napomenuti da je u koraku smanjenja za vrijeme lijevanja, brzina ulijevanja materijala konstantna.
A product for the biological control of phytopathogenic fungi and stimulating plant growth according to claim 3, containing a total spore concentration greater than 109 CFU/mL. 
Proizvod za biološku kontrolu fitopatogenih gljivica i stimuliranje rasta biljaka temeljem zahtjeva 7, naznačen time što je stabilnost osigurana putem mikrobnog rasta inhibitorskih supstanci.
The composition according to claim 4, wherein the heparan sulfate is present between 0.5% by weight and 1% by weight-based on the total weight of the cosmetological and dermatological composition. 
3. < Dermatološki pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je heparan sulfat prisutan u koncentraciji koja se kreće između 0,5% 1 1% ukupne mase.
receiving a first downlink signal comprising information indicating a plurality of uplink access configurations, each uplink access configuration including a random access configuration; 
primanju prvog signala silazne veze koji sadrži informacije koje ukazuju na više konfiguriranja pristupanja uzlaznoj vezi, gdje svako konfiguriranje pristupa uzlaznoj vezi uključuje konfiguriranje sa slobodnim pristupom;
A dried mixture produced by the method of claim 15 . 
Sušena homogena smjesa proizvedena postupkom sukladno zahtjevu 11.
The transdermal delivery device of items 1 or 3, wherein the microspheres are uniformly dispersed in within the drug layer. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da su mikrosfere ravnomjerno dispergirane unutar sloja koji sadrži lijek.
A humanised antibody of claim 6 comprising a heavy chain of SEQ ID NO:19 and a light chain of SEQ ID NO:23. 
Humanizirano protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što sadrži teški lanac sa SEQ ID NO:19 i laki lanac sa SEQ ID NO:23.
The anti-PD-1 antibody or the antigen-binding fragment thereof according to claim 14, wherein the heavy chain variable region of the humanized antibody further comprises a heavy chain FR sequence of human IgG1, IgG2, IgG3 or IgG4, or a variant thereof. 
PD-1 protutijelo ili njegov fragment koji se veže na antigen sukladno patentnom zahtjevu 1, pri čemu je to protutijelo ili njegov fragment koji se veže na antigen humanizirano protutijelo.
Persons experiencing a psychosis may experience hallucinations, hold paranoid or delusional beliefs, demonstrate personality changes and exhibit disorganized thinking. 
Osobe u psihozi mogu imati halucinacije, paranoidna 1li iluzijska vjerovanja, pokazuju promjene osobnosti i neorganiziranost mišljenja.
The IL-17 binding antibody or active fragment thereof according to claim 2, wherein said VH comprises in sequence hypervariable regions CDR1-x, CDR2-x and CDR3-x, said CDR1-x having the amino acid sequence SEQ ID NO:11, said CDR2-x having the amino acid sequence SEQ ID NO:12, and said CDR3-x having the amino acid sequence SEQ ID NO:13 or direct CDR-x equivalents thereof. 
VL koji obuhvaća u nizu hipervarijabilna područja CDR1’, CDR2’ i CDR3’, gdje navedeno područje CDR1’ ima aminokiselinsku sekvencu SEQ ID NO:4, navedeno područje CDR2’ ima aminokiselinsku sekvencu SEQ ID NO:5, i navedeno područje CDR3’ ima aminokiselinsku sekvencu SEQ ID NO:6, dok su hipervarijabilna područja određena prema Kabat-definiciji.
Further, the present invention encompasses a method of identifying compounds suitable for active immunization of a patient predicted to develop Alzheimer's Disease. 
Metoda identifikacije spojeva podobnih za aktivnu imunizaciju pacijenta za kojeg se očekuje da razvije
ET-701 impurity production in different formulations stored during 3 months at 5°C. 
Proizvodnja ET-701 nečistoće u različitim oblicima čuvanim u trajanju od 3 mjeseca na 5?C.
comprises heavy chain CDR 1, 2 and 3 sequences as set forth in SEQ ID NOs: 1, 2 and 3 respectively, and light chain CDR 1, 2 and 3 sequences as set forth in SEQ ID NOs: 4, 5 and 6 respectively; 
sadržava CDR nizove 1, 2 i 3 teškog lanca, kako je izloženo u SEQ ID NOs: 1, 2 i 3, i CDR nizove 1, 2 i 3 lakog lanca kako je navedeno u SEQ ID NOs: 4, 5 i 6 kuna;
The process of claim 1, wherein the step of neutralizing volatile acids includes adding Sodium Hydroxide solution until pH value of the mixture reaches value between 8.1 and 8.5. 
Postupak prema zahtjevu 1, naznačen time da korak neutralizacije hlapljivih kiselina obuhvaća dodavanje otopine natrijev hidroksida sve dok pH vrijednost mješavine ne bude između 8,1 18,5.
The hot steam always remains in the thermoblock 10 such that hot steam is always available on demand. 
Vruća vodena para uvijek ostaje u termobloku 10, tako da je vruća vodena para uvijek dostupna na zahtjev.
An isolated human monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody specifically binds to human IP-10 and does not cross-react with human MIG and does not cross-react with human ITAC. 
Izolirano humano monoklonsko antitijelo, ili njegov antigen-vežući dio, naznačeno time što se antitijelo specifično veže za humani IP-10 i ne reagira unakrsno sa humanim MIG 1 ne reagira unakrsno sa humanim ITAC.
Within the space of the longitudinally spread blank of the cigarette box the following walls are situated: front, upper and bottom with attached thereto side walls, whereas the lid walls, rear storage space wall together with attached thereto side walls are adjacent, and the rear wall adjoins the bottom wall, whereas said bottom wall is adjacent to the front storage space wall. The box features additional cut-out in the inside part formed of the inside front wall and adjacent side walls and the bottom wall. 
Unutar prostora sheme kutije za cigarete pružene vodoravno nalaze se sljedeći zidovi: prednji, gornji i donji zidovi poklopca zajedno sa bočnim zidovima pričvršćenim na njih, stražnji zid spremišnog prostora zajedno sa bočnim zidovima pričvršćenim na njega, stražnji zid, donji zid i prednji zid spremišnog prostora; a zidovi poklopca i navedeni stražnji zidovi spremišnog prostora graniče, stražnji zid je spojen sa navedenim donjim zidom, donji zid graniči sa prednjim zidom spremišnog prostora.
A method for making a humanized murine animal, comprising replacing all murine exons encoding ectodomain sequences of murine IL-6Ra with a human genomic fragment encoding human IL-6Ra ectodomain to form a humanized IL-6Ra gene, wherein the humanized IL-6Ra gene is under control of endogenous murine regulatory elements. 
Postupak za stvaranje humaniziranog miša, naznačen time da sadrži zamjenu svih mišjih eksona koji kodiraju sekvence ektodomene za mišji IL-6Ra sa ljudskim genomskim fragmentom koji kodira ljudsku ektodomenu IL-6Ra da se dobije humanizirani IL-6Ra gen, pri čemu je humanizirani IL-6Ra gen pod kontrolom regulacijskih elemenata endogenog miša.
Non-esterified free-fatty acid (NEFA) assays were done on serum derived from live, freely moving rats. 
Ispitivanje ne-esterificirane slobodne masne kiseline (NEFA) je provedeno na serumu dobivenom iz živih štakora koji se slobodno kreću.
combining at least 
(a) kombiniranje barem
The panel according to claim 4 wherein the upper plateau is concave. 
Ploča prema zahtjevu 10, naznačena time što je gornja ploha (7) konkavna.
In some embodiments, the amide is the N,N-dialkylformamide and the conditions suitable for forming the amide solvate of the compound of formula II comprise contacting the acid solvate with the tertiary amide at a temperature of between about 20° C. and about 50° C. In some embodiments, the amide is N,N-dimethylformamide (DMF) and the conditions suitable for forming the amide solvate comprise re-slurrying the acid solvate in the DMF at a temperature of about 40° C. 
Postupak prema zahtjevu 5, naznačen time da amid je N,N-dialkilformamid; te pogodni uvjeti za nastanak amidnog solvata spoja s formulom II obuhvaćaju temperaturu od između oko 20 "C i oko 70 "C; poželjno pri čemu: amid je N,N-dimetilformamid (DMF); i t pogodni uvjeti za nastanak amidnog solvata obuhvaćaju ponovno suspendiranje kiselog solvata u DMF kod temperature od oko 50 "€.
A preferred non-repressing carbon source is selected from the group consisting of alanine, mannitol, sorbitol, trehalose, lactose and combinations thereof. 
Postupak prema bilo kojem zahtjevu od 11 do 17, naznačen time, da je neograničavajući izvor ugljika odabran iz skupine koja sadrži alanin, manitol, sorbitol, trehaloza, laktoza i njihova kombinacija.
After assembly the shell 14 is thermally bonded at one or more bonding spots or bonding areas 1, 2 which are located within the contact path 3. This is illustrated, for example, in Figure 6 as the spot weld 53, where the shell is bonded to the cup body shoulder 32 or the annular outer surface 38 adjacent its lower edge 41. 
Nakon sklapanja ljuska 14 se termički spaja na jednoj točki spajanja ili na više točaka spajanja ili na jednom mjestu spajanja ili na više mjesta spajanja 1,2 koji su prikazani, na primjer, na slici 6 kao mjesto točkastog zavarivanja 53, gdje je ljuska spojena na izbočinu 32 tijela čaše ili na vanjsku prstenastu površinu 38 koja se nalazi uz njezin donji rub 41, to jest na razmaku od oko 5 mm od zavijutka 34.
In this regard, the invention has advantageously solved, thanks to refinements in the injection-molding process, problems linked to the seepage of melted polymeric material in regions intended for vapor permeation, thus ensuring high standards of breathability. 
U tom su smislu predmetnim izumom, zahvaljujući poboljšanjima u postupku injektivnog prešanja, na povoljan način riješeni problemi povezani s istjecanjem rastaljenog polimernog materijala u područjima koja su namijenjena propuštanju pare, čime se osigurava visoka razina propusnosti.
The process according to any one of claims 1 to 5, characterized in that said calcium-carbonate containing material of step a) is provided in the form of an aqueous suspension, preferably having a content of calcium carbonate containing material within the range of 1 wt.-% to 79 wt.-%, more preferably 3 wt.% to 78 wt.%, and even more preferably 55 wt.-% to 75 wt.-%, based on the weight of the suspension. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time da je navedeni materijal koji sadrži kalcijev karbonat iz koraka a) osiguran u obliku vodene suspenzije, te poželjno ima udio materijala koji sadrži kalcijev karbonat u rasponu od 1 tež-% do 79 tež-%, poželjnije 3 tež.% do 78 tež.%, te još poželjnije 55 tež-% do 75 tež- %, temeljeno na težini suspenzije.
FEC decoding the bit-deinterleaved L1 signaling data. 
FEC dekodiranje podataka cijevi fizičke razine raspletenih bitova.
A method according to claim 1, wherein the melt has a composition comprising the following, expressed by weight of oxides: 
Postupak sukladno patentnom zahtjevu 1, pri čemu otopina ima sastav koji sadrži slijedeće, izraženo težinom (wt) oksida:
receptor antagonists, selected from the group of: 
- < antagonisti B2 receptora koji su odabrani iz sljedeće skupine:
The CO2 cartridge is activated by the pressure from the lid, for example by puncturing a seal or by operating a ball valve in the CO2 cartridge, as shown in Fig. 3. 
CO; patrona se aktivira pritiskom sa poklopca, na primjer bušenjem brtve ili djelovanjem kuglastog ventila u CO; patroni, kao što je prikazano na slici 3.
A compound according to claim 1 for use in the treatment of ovarian cancer. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je hiper-proliferativni poremećaj rak jajnika.
three (3) Taxol molecules are conjugated to said polypeptide, and 
(b) tri (3) molekule Taxola su konjugirane na navedeni polipeptid, 1
Ra and Rb are independently selected from the group consisting of hydrogen, C1-6alkyl, and C1-6alkoxycarbonyl; or, when Ra and Rb are other than hydrogen, Ra and Rb are optionally taken together with the nitrogen to which they are both attached to form a five to eight membered monocyclic ring; and 
ili kada Ra i Rb nisu vodik, Ra i Rb su proizvoljno uzeti zajedno sa dušikom za koji su oba vezani da formiraju peto- do osmo-člani monociklični prsten; i L je izabran iz grupe koju čine O, S i N (Rd); gdje Rd predstavlja vodik, C1-6 alkil, ili aril.
The composition of claim 11 comprising 0.01 to 60% by weight of a solid or encapsulated pesticidally active ingredient. The composition of claim 9 wherein the composition is obtained by diluting a concentrated formulation comprising at least one solid or encapsulated pesticidally active ingredient in a liquid carrier, wherein surfactants a) and b), individually, are present in said concentrated formulation, added separately to the liquid carrier or a combination thereof. 
Pripravak prema zahtjevu 9 naznačen time da se pripravak dobiva razrjeđivanjem koncentrirane formulacije i sadrži barem jednu krutu ili enkapsuliranu pesticidno aktivnu tvar u pogodnoj količini tekućeg nosača da se dobije željena koncentracija barem jedne krute ili enkapsulirane pesticidno aktivne tvari, pri čemu su surfaktanti a) i b), pojedinačno prisutni u navedenoj koncentriranoj formulaciji, koja se dodaje odvojeno u tekući nosač ili u njihovu kombinaciju.
Example 11 Clinical Efficacy in Epilepsy 
Primjer 11: Klinička učinkovitost u epilepsiji
Number of C atoms Top 30 Candidates 
(21) Broj predmeta:
The method of claim 12, wherein said disease is cancer induced bone metastasis. A method for the treatment of disease states associated with osteoporosis, hypercalcemia, cancer induced bone metastasis, Paget's disease or adjuvant or neoadjuvant cancer therapies comprising the step of administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 2 . 
Molekularni kompleks prema zahtjevu 1 ili zahtjevu 2, pripravak prema zahtjevu 3 ili zahtjevu 4, ili farmaceutski pripravak prema bilo kojem od zahtjeva 5 do 6 naznačen time da je za uporabu za liječenje i/ili sprječavanje bolesnih stanja povezanih s osteoporozom, hiperkalcemijom, metastazama kostiju izazvanih rakom, Pagetovom bolešću ili adjuvantnim ili neoadjuvantnim terapijama raka.
The isolated antibody or antibody fragment thereof according to claim 1 for use in treating a hematological cancer selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myeloid leukemia, B-cell lymphoma, and Burkitt's lymphoma. 
Izolirano protutijelo u skladu s patentnim zahtjevom 1, naznačeno time da je navedeni hematološki karcinom odabran iz skupine koju čine multipli mijelom, kronična limfoblastična leukemija, kronična limfocitna leukemija, leukemija stanica plazme, akutna mijeloidna leukemija, kronična mijeloidna leukemija, limfom B stanica 1 Burkittov limfom.
The mooring buoy of claim 13, wherein the mooring position is obtained by a mooring line of a marine vessel being attached to the attachment point. 
Plutača za privez (101) prema zahtjevu 13, naznačena time što se položaj za privez postiže vezanjem plovila (1004) na mjesto pričvršćenja (209).
The bioadhesive polymers are selected from the group of natural polymers, polysaccharides, chitosan, alginate, carboxymelthyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, cyclodextrin, sodium hyaluronate, xanthum gum, natural proteins from animal origin or vegetable origin, natural milk proteins, natural pea proteins, natural soy proteins, natural potato proteins, natural wheat proteins, gliadin proteins, synthetic polymers, carbomer, polyvinylalcohol, acrylic polymers and mixtures thereof. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što najmanje jedan bioadhezivni polimer sadrži prirodne proteine izabrane iz grupe koju čine prirodni proteini mlijeka, karbomer, alginat, hitosan, ksantan guma, hidroksipropil celuloza, polivinilalkohol, karboksimetil celuloza, hidroksipropil metil celuloza, hidroksietil celuloza, natrij-hijaluronat, akrilni polimeri i njihove smjese.
The process of any one of claims to wherein the vaccine is a monovalent pandemic influenza vaccine. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest monovalentno cjepivo protiv pandemijske gripe.